Background: Bipolar depression presents remains a major clinical challenge with limited evidence-based treatment options. Pramipexole, a dopamine D2/D3 receptor agonist with preferential D3 affinity, has shown antidepressant properties in small randomized controlled trials (RCTs), particularly among patients with previous treatment failure or treatment-resistant bipolar depression (TRBD). However, a quantitative synthesis is lackingcan clarify aggregate effects. Methods: We systematically searched MEDLINE, Embase, PsycINFO, and CENTRAL through August 2026, for RCTs of adjunctive pramipexole in adults with bipolar depression. Co-primary outcomes were change in depressive symptom severity and treatment response. Secondary outcomes included remission, tolerability, and safety (including manic/hypomanic switch). Risk of bias was assessed using the Cochrane RoB 2 tool. Continuous and dichotomous outcomes were pooled using random-effects meta- analysis; heterogeneity was assessed with I² statistic. Results: Three RCTs (N=82; mean age 44.6±10.7 years; 55% female) were included. Two of the three trials (66.7%) met their primary efficacy endpoint. Adjunctive pramipexole significantly improved depressive symptom severity (Hedges' g=−1.38, 95%CI −2.49 to −0.26; I²=74.9%) and increased treatment response (ORRR=4.99, =2.89, 95%CI 1.42–17.531.24–6.71; I²=13.6%)0.0%), compared to placebo. Remission (OR=1.75, 95%CI 0.47–6.44RR=1.57, 95%CI 0.52–4.76) and manic/hypomanic switch (OR=1.76, 95%CI 0.57–5.48RR=1.51, 95%CI 0.71–3.20) did not differ significantly. No individual adverse event was significantly associated with pramipexole, although safety data were sparse and heterogeneously reported. Conclusions: Adjunctive pramipexole demonstrated preliminary efficacy for depressive symptom reduction and treatment response in bipolar depression. However, substantial heterogeneity, sensitivity to individual studies, and limited safety data preclude firm conclusions. Larger RCTs are needed to clarify its clinical role, particularly in patients with previous treatment failure or TRBD.
Presupposti dello studio: la depressione bipolare rimane una rilevante sfida clinica, con opzioni terapeutiche basate su evidenze ancora limitate. Il pramipexolo, agonista dei recettori dopaminergici D₂/D₃ con affinità preferenziale per D₃, ha mostrato proprietà antidepressive in piccoli trial randomizzati controllati (RCT). Tuttavia, manca una sintesi quantitativa aggiornata degli RCT che hanno valutato il pramipexolo in augmentation nella depressione bipolare che potrebbe chiarificare gli effetti aggregati. Materiali e metodi: abbiamo effettuato una ricerca sistematica in Ovid MEDLINE, Embase, APA PsycINFO e CENTRAL dall'inizio dell'indicizzazione fino al 25 agosto 2026 per individuare RCT sul pramipexolo in augmentation in adulti con depressione bipolare. Gli esiti primari erano la variazione della gravità dei sintomi depressivi e la risposta al trattamento. Gli esiti secondari comprendevano remissione, tollerabilità e sicurezza, incluso lo switch maniacale/ipomaniacale. Il rischio di bias è stato valutato mediante lo strumento Cochrane Risk of Bias 2. Gli esiti continui e dicotomici sono stati aggregati mediante metanalisi a effetti casuali; l'eterogeneità è stata valutata con la statistica I². Risultati: sono stati inclusi tre RCT (N = 82; età media 44.6 ± 10.7 anni; 55% di sesso femminile). Il pramipexolo in aggiunta è risultato significativamente superiore al placebo per la variazione dei sintomi depressivi (g di Hedges = −0,73 IC 95% da −1,19 a −0,26; I² = 0%) e per la risposta al trattamento (RR = 2,89, IC 95% 1,24–6,71; I² = 0%). La remissione (RR = 1,64, IC 95% 0,54–5,01) e lo switch maniacale/ipomaniacale (RR = 1,51, IC 95% 0,71–3,20) non differivano significativamente tra i gruppi. Nessun singolo evento avverso era associato in misura significativa al pramipexolo, sebbene i dati sulla sicurezza fossero scarsi e riportati in modo eterogeneo. Conclusioni: nella depressione bipolare, il pramipexolo in aggiunta è risultato associato a miglioramenti significativi dei sintomi depressivi e della risposta al trattamento. Tuttavia, l'entità del beneficio rimane incerta a causa della sostanziale eterogeneità clinica, della ridotta base di evidenze e della sensibilità ai singoli studi. Nel breve termine non sono emerse differenze statisticamente significative negli esiti di sicurezza e tollerabilità; tuttavia, la scarsità e l’eterogeneità dei dati non consentono conclusioni definitive. Sono necessari RCT più ampi per chiarire il ruolo clinico del pramipexolo in aggiunta nella depressione bipolare.
Pramipexolo in aggiunta nella depressione bipolare resistente al trattamento: una revisione sistematica e metanalisi di studi randomizzati controllati.
POLETTO, MATTEO
2024/2025
Abstract
Background: Bipolar depression presents remains a major clinical challenge with limited evidence-based treatment options. Pramipexole, a dopamine D2/D3 receptor agonist with preferential D3 affinity, has shown antidepressant properties in small randomized controlled trials (RCTs), particularly among patients with previous treatment failure or treatment-resistant bipolar depression (TRBD). However, a quantitative synthesis is lackingcan clarify aggregate effects. Methods: We systematically searched MEDLINE, Embase, PsycINFO, and CENTRAL through August 2026, for RCTs of adjunctive pramipexole in adults with bipolar depression. Co-primary outcomes were change in depressive symptom severity and treatment response. Secondary outcomes included remission, tolerability, and safety (including manic/hypomanic switch). Risk of bias was assessed using the Cochrane RoB 2 tool. Continuous and dichotomous outcomes were pooled using random-effects meta- analysis; heterogeneity was assessed with I² statistic. Results: Three RCTs (N=82; mean age 44.6±10.7 years; 55% female) were included. Two of the three trials (66.7%) met their primary efficacy endpoint. Adjunctive pramipexole significantly improved depressive symptom severity (Hedges' g=−1.38, 95%CI −2.49 to −0.26; I²=74.9%) and increased treatment response (ORRR=4.99, =2.89, 95%CI 1.42–17.531.24–6.71; I²=13.6%)0.0%), compared to placebo. Remission (OR=1.75, 95%CI 0.47–6.44RR=1.57, 95%CI 0.52–4.76) and manic/hypomanic switch (OR=1.76, 95%CI 0.57–5.48RR=1.51, 95%CI 0.71–3.20) did not differ significantly. No individual adverse event was significantly associated with pramipexole, although safety data were sparse and heterogeneously reported. Conclusions: Adjunctive pramipexole demonstrated preliminary efficacy for depressive symptom reduction and treatment response in bipolar depression. However, substantial heterogeneity, sensitivity to individual studies, and limited safety data preclude firm conclusions. Larger RCTs are needed to clarify its clinical role, particularly in patients with previous treatment failure or TRBD.| File | Dimensione | Formato | |
|---|---|---|---|
|
Poletto_Matteo.pdf
Accesso riservato
Dimensione
1.89 MB
Formato
Adobe PDF
|
1.89 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/119766